Clinical response to ICIs is predicated on PD-L1 expression and the density of tumor-infiltrating lymphocytes (TILs), with a correlation between the primary tumor and BMs in lung adenocarcinoma (33–37). The gene discussed is CD274; the disease is lung adenocarcinoma.